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Figure 1. panendoscopy finding: a fungating mass in the 
esophagus.
Since the first case report was published by Baur in 1906,1 primary malignant melanoma of the esophagus has been considered an extremely rare 
cancer. Among esophageal cancers, primary malignant 
melanoma accounts for 0.1%l0.2% of cases.2 We have 
used CT and positron emission tomography (PET) 
scans to evaluate metastasis. According to previous rel
ports, the rate of metastasis is high when the tumor is 
first diagnosed.3 Use of PET obviously increases the 
accuracy of staging. Although primary malignant melal
noma of the esophagus is now better understood, the 
5lyear survival rate is dismal and treatment remains 
challenging.
CASe
A 40lyearlold woman with 3 months of dysphagia, myl
algia over the subscapular region on the left side, and 
body weight loss (9 kg) was diagnosed with primary 
malignant melanoma of the esophagus by panendosl
copy (PES) with biopsy (Figure 1). After the cancer was 
confirmed, CT, whole body bone scans and PET scans 
(Figure 2) were used to establish the clinical stage. An 
upper gastrointestinal (GI) series was also used to asl
sess the axis of the esophagus and the mucosal lesion. 
The tumor was located about 25 to 30 cm from the incil
sors with a segmental filling defect and mucosal destrucl
tion evident in the upper GI series. Chest CT showed 
wall thickening and a softltissue lesion over the middle 
third of the esophagus, extending for more than 5 cm. 
Extratumoral extension and lymph node metastasis 
were considered. PET scans showed bifocal 2l[18F]l
Fluorol2ldeoxylDlglucose (FDG) uptake about the 
middle third of the esophagus and increased uptake in 
the right lowerlneck region. Tumor markers including 
carcinoembryonic antigen and squamous cell carcinoma 
markers were negative.
The patient received subtotal esophagectomy 
and lymph node dissection after a series of studies. 
Reconstruction of the esophagus with a gastric tube 
(substernal route) with cervical esophagogastrostomy 
was performed after the first step of the operation. A 
solid fixed lymph node about 3.5×2 cm was noted and 
dissected. The resected esophageal specimen was 10.5 
cm in length and a fungating mass about 4×3.5×2.5 
cm was evident in the specimen (Figure 3). The final 
pathology report indicated that the mass was a maligl
nant melanoma invading to the submucosal layer and 
characterized by vesicular hyperchromatic nuclei with 
prominent eosinophilic nucleoli and frequent mitosis. 
Immunohistochemical stains for HMBl45 antigen and 
Sl100 protein were positive. The surgical margins were 
free of tumor invasion, but lymph nodes were noted to 
contain tumor emboli. We took a biopsy of the cervical 
lymph node on the basis of the PET findings and, unforl
tunately, a metastasis was found.
DISCUSSIOn
Primary malignant melanoma of the esophagus is a rare 
and aggressive tumor with a poor prognosis. Only 15% 
of all melanomas are encountered in noncutaneous sites,4 
with 0.5% of these arising in the esophagus.5 Primary 
malignant melanoma of the esophagus was widely acl
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Figure 3. Operative finding and specimen.
Figure 2. peT scan image: FDG-avid tumor in the middle third of 
the esophagus, and another FDG-avid lesion localized in the right 
neck region, level 4.
cepted after de la Pava et al demonstrated the presence 
of melanocytes in normal esophageal mucosa in 1963.6 
In 1953, Allen and Spitz developed histological criteria 
for primary esophageal malignant melanoma, which eml
phasized the presence of junctional epithelial changes in 
the overlying or juxtaposed epithelium near the tumors.7 
No more than 300 cases have been reported worldl
wide since 1906, most of which were in individual case 
reports. The symptoms included dysphagia (79.8%), 
weight loss (37.5%), substernal or epigastric discomfort 
or pain (33.1%) and melena (7%). Some patients were 
asymptomatic. The mean duration of symptoms was 3.2 
months. It has been shown that esophageal melanocyl
tosis is mostly located in the middle and lower thirds of 
the esophagus and most of malignant melanomas are 
located over this area.8 Endoscopic biopsy yields diagl
nostic specimens only 50% of the time.4 The histopathol
logical diagnosis is not established until after resection 
is performed.
Despite our growing understanding of this maligl
nant disease, the prognosis of esophageal melanoma rel
mains poor, with a 5lyear survival rate after surgery of 
4.2%.8 This is most likely because of the advanced state 
of these tumors at the time of diagnosis, with metastal
ses commonly seen. The common sites of metastases are 
the liver (31%), the mediastinum and mediastinal lymph 
nodes (29%), the lung (17.7%) and the brain (13.2%).3 
For lymph node metastasis, FDG PET detected 100% 
of metastases ≥10 mm, 83% of metastases 6l10 mm, and 
23% of metastases <5 mm. Moreover, FDG PET has 
high sensitivity (≥93%) only for metastases with more 
than 50% lymph node involvement or with capsular inl
filtration.2 The choice of treatment for this condition is 
mainly dependent on the patient’s functional status and 
the presence and extent of metastatic disease at the time 
of diagnosis.10 Surgical resection with total esophagecl
tomy remains the main component of management, 
even in cases of recurrence. Although radiotherapy and 
chemotherapy have not proven to be beneficial, they play 
a palliative role after surgical consideration.11 Our case 
demonstrates the importance of PET, which is helpful 
in finding metastasis to the cervical node. In our opinl
ion, PET should be used in those who are diagnosed 
with primary malignant melanoma of the esophagus 
that may increase the accuracy of staging.
This article is a reprint that was originally published in the 
Annals of Saudi Medicine 2008; 28(6): 458-460.
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